Sino Biological Launches Antigens for 2026-2027 Influenza Vaccine Strains Following WHO Recommendations

The World Health Organization has announced its recommendations for the 2026–2027 Northern Hemisphere influenza vaccine composition, highlighting two key developments: the continued spread of A (H3N2) subclade K and the growing circulation of new B/Victoria lineage strains. In response, Sino Biological has launched a comprehensive panel of antigens for these strains to accelerate influenza vaccine development.

Since its identification in August 2025, H3N2 subclade K has become the dominant influenza A strain worldwide. Defined by the T135K and S144N mutations, this strain exhibits enhanced immune escape, prompting WHO’s selection of A/Darwin/1454/2025 as the new H3N2 reference viruses. The H1N1 component has been updated to A/Missouri/11/2025.

Influenza B activity is rising sharply, with the proportion of B/Victoria lineage viruses increasing from 6% to over 20% in regions such as Hong Kong and the U.S. These trends led WHO to recommend B/Tokyo/EIS13-175/2025 and B/Pennsylvania/14/2025 strains for the upcoming season.

Sino Biological’s portfolio includes recombinant antigens spanning key viral antigens including Hemagglutinin, Neuraminidase, and Nucleoprotein. For H1N1, A/Missouri/11/2025 HA Trimer, NA, and NP antigens are available now. For H3N2 subclade K, recombinant HA, NA, and NP aligned with A/Darwin/1454/2025 are also available. Influenza B reagents for B/Tokyo/EIS13-175/2025 and B/Pennsylvania/14/2025 are in development. The company provides stable HA trimers that maintain native conformation for accurate immune characterization.

Dr. Rob Burgess, Chief Business Officer at Sino Biological US, stated that the company’s mission is to provide the scientific community with high-quality tools rapidly when infectious disease evolution threatens global health preparedness. More information about the company can be found at https://www.sinobiological.com. The original release is available on https://www.newmediawire.com.

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Sino Biological Launches Antigens for 2026-2027 Influenza Vaccine Strains Following WHO Recommendations.

The post Sino Biological Launches Antigens for 2026-2027 Influenza Vaccine Strains Following WHO Recommendations appeared first on citybuzz.